Eli Lilly News

24.12 / 09:07

markets COST UPS Research country patient Pharmaceuticals Competition will make weight-loss drugs better, cheaper and bigger

Subscribe to enjoy similar stories. Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking remedies for erectile dysfunction and hair loss. Since May it has offered its own version of Wegovy, a blockbuster slimming jab, thanks to a quirk in American law that lets pharmacies replicate some brand-name drugs when there are shortages.

23.12 / 05:25

markets UPS SUN security show exclusive Pharmaceuticals Weight-loss drugs: A game changer for India’s top pharma companies

Subscribe to enjoy similar stories. Over 650 million adults globally suffer from obesity, and this number is only expected to rise. Simultaneously, the market for weight-loss drugs is experiencing a revolutionary shift, driven by advances in treatments like Ozempic, Wegovy, and Zepbound—three drugs that are showing remarkable results in combating obesity.

04.12 / 16:03

markets Provident Software show performer reports patient Zepbound: The new weight loss pill that’s set to beat Wegovy, according to Eli Lilly

Eli Lilly’s weight loss drug, Zepbound, has been shown to lead to more significant weight loss than Novo Nordisk’s Wegovy, according to results from a new clinical trial. The study, funded by Lilly, is the first to compare the two drugs directly, providing valuable insights into their efficacy for weight loss. Lilly announced the results on Wednesday, claiming that Zepbound outperforms Wegovy, which has been a leader in the weight loss market.

04.12 / 13:37

markets UPS Fighting testing patient Eli Lilly’s Zepbound beats Novo Nordisk’s Wegovy in first head-to-head study

Subscribe to enjoy similar stories. In the first head-to-head test, Eli Lilly’s Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk’s Wegovy. People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

01.12 / 10:19

markets UPS wellness Amgen show reports patient Eli Lilly and Novo Nordisk’s obesity moat just got stronger

Subscribe to enjoy similar stories. The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds competition to a market currently controlled by Eli Lilly and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy and Zepbound.

18.11 / 09:37

markets Provident Manufacturing innovations patient medicines Pharmaceuticals Eli Lilly and Novo want to shake off Ozempic copycats. Are they ready to meet demand?

Subscribe to enjoy similar stories. Pharmaceutical companies are typically rewarded for their innovation with years of market exclusivity before cheaper generics enter the scene. But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost immediately.

04.11 / 12:53

markets Manufacturing wellness Amgen reports testing patient Big Pharma’s obesity bonanza faces new tests

Subscribe to enjoy similar stories. In terms of recent stock-market frenzies, the Ozempic trade nearly tops the list, second only to speculation that artificial intelligence will soon be writing this column. Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most of those gains flowing to Eli Lilly and Novo Nordisk, the dominant players in the obesity-drug market.

02.11 / 00:37

markets COST UPS Aviat Airlines Sustainability Destiny Rakesh Gangwal: the airline industry disciplinarian behind IndiGo’s success

Subscribe to enjoy similar stories. A market share of 50% in a highly competitive industry is a rarity. Of all the major Indian companies, only two, Asian Paints and IndiGo, have managed that consistently.

31.10 / 00:53

UPS DOW reports How major US stock indexes fared Wednesday, 10/30/2024

U.S. stock indexes gave up an early gain and ended slightly lower following a mixed set of profit reports from giants like Google’s parent company and Eli Lilly

30.10 / 14:37

markets UPS Booking wellness Pharmaceuticals Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations

27.10 / 05:35

Food wellness Instagram Universities beautiful Discrimination rights The economics of thinness (Ozempic edition)

Subscribe to enjoy similar stories. Arriving in Stepford, Connecticut, Joanna—protagonist of “The Stepford Wives", a horror novel—is dragged to a “workout class" at the Simply Stepford Day Spa by a neighbour. The duo are met by 15 identikit women.

25.10 / 12:33

Target Food Research Danone wellness love reports Big food is learning to love weight-loss drugs

Subscribe to enjoy similar stories. A new class of weight-loss drugs is changing the food industry, but not in the way many expected at first. They could present just as many opportunities as pitfalls.

21.10 / 17:21

ETF SEC CEO Strategy Morningstar Bill Equality KKM Financial's Essential 40 stock fund is now an ETF

KKM Financial has converted its Essential 40 mutual fund into an ETF, joining the growing shift by asset managers to a more tax-efficient fund model.

17.10 / 13:55

UPS Analysis Research show patient Weight-loss drugs cut drug and alcohol abuse, according to new study

Subscribe to enjoy similar stories. Drugs such as Novo Nordisk’s blockbuster Ozempic can cut drug and alcohol abuse by up to 50% according to a new study, adding to mounting evidence that the drugs yield health benefits beyond diabetes and weight loss.

08.10 / 19:08

markets UPS FIVE Digital Manufacturing Election US co Amneal plans units in India for weight-loss drugs

Amneal Pharmaceuticals, the third largest generic drugmaker in the US, plans to invest $150-200 million over the next four to five years to build a manufacturing facility in Ahmedabad housing two greenfield plants for producing weight loss drugs.

20.09 / 10:25

markets COST UPS War cover patient medicines The price war in weight-loss drugs is here

Subscribe to enjoy similar stories. A price battle has broken out in the hot market for weight-loss drugs. Eli Lilly and Novo Nordisk, the pharmaceutical heavyweights selling the popular injections, are each dangling discounts to gain an edge and to induce health plans to pay up.

18.08 / 06:39

markets UPS Provident Extreme NVIDIA Trade Cycling Limited exposure to Wall Street megacaps insulated us from drawdown: Arindam Mandal of Marcellus

Global Compounders fund has outperformed the S&P 500 by a wide margin by keeping limited exposure to megacaps. «This positioning has insulated us from the recent drawdown and volatility. The megacaps, including not only the big tech names but also companies like Eli Lilly and Costco, have been bid up to extremely high valuations due to their certainty around growth and earnings delivery in near term,» says Arindam Mandal, Portfolio Manager at Marcellus Investment Managers.

08.08 / 21:50

CEO wellness reports patient Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarter

Eli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker

08.08 / 21:43

markets UPS DOW economy Updates How major US stock indexes fared Thursday, 8/8/2024

U.S. stocks rallied to their best day since 2022 following an encouraging update on the job market

08.08 / 17:20

markets UPS economy trends stage reports jobless claims Relief rally for stocks as markets digest jobless claims data

Stocks staged a relief rally and bonds fell after the latest US labor-market reading helped ease fears about a more pronounced slowdown in the world’s largest economy.

01.08 / 12:46

markets Trade performer F&C outperforms benchmark in first half of 2024 aided by US large-cap exposure

In its half-year results published today (1 August), the £6bn trust posted a net asset value total return of 13.2%, against the FTSE All-World index's 12% gain. US large-cap companies within F&C's North American portfolio returned 25.7%, compared to the 21.9% recorded by the Russell 1000 growth index, with top performers such as Eli Lilly and Meta contributing the most to the vehicle's returns. «While the fundamental backdrop is constructive and the US recession has been avoided, global equity markets, dominated by the US, continue to trade at historically elevated valuation levels,»...

facts about Eli Lilly

Who is Eli Lilly?

Eli Lilly is a media figure featured in various informative articles related to trending topics.

Why is Eli Lilly attracting attention?

Eli Lilly frequently draws public interest due to noteworthy actions, which sparks conversations.

Where can I find the latest news about Eli Lilly?

Our website has a dedicated section featuring all recent updates related to Eli Lilly. We continuously monitor developments and update the information in real time.